Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.

ABSTRACT:

Background

Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid-lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We performed a systematic review and meta-analysis of RCTs on the efficacy and safety of volanesorsen as compared to placebo treatment in patients with severe HTG.

Methods

Studies were systematically searched in the PubMed, Web of Science and Scopus databases according to PRISMA guidelines. The last search was performed on 7 February 2022.

Results

Four studies showed significant reduction in TG after 3 months of treatment with volanesorsen as compared with placebo (MD: -73.9%; 9

SUBMITTER: Calcaterra I 

PROVIDER: S-EPMC9788245 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature